Company Overview: Soleno Therapeutics and Its Lead Product
Soleno Therapeutics (NASDAQ: SLNO) is a biopharmaceutical company focused on rare diseases, primarily known for diazoxide choline extended-release (DCCR) tablets, branded as VYKAT™ XR, to treat hyperphagia in Prader-Willi Syndrome (PWS) (www.globenewswire.com). PWS is a genetic disorder that leads to insatiable appetite and obesity; Soleno has described hyperphagia as “the most life-limiting aspect” of PWS (www.globenewswire.com). DCCR/VYKAT XR is essentially Soleno’s only commercial product – the company has no other marketed drugs (www.globenewswire.com). After a Phase 3 trial, Soleno’s New Drug Application (NDA) for DCCR was accepted with Priority Review by the FDA in 2024. Approval was granted on March 26, 2025, making VYKAT XR the first FDA-approved therapy for hyperphagia in PWS (investors.soleno.life) (investors.soleno.life). Soleno rapidly built a commercial infrastructure in anticipation of launch, hiring sales and medical affairs teams and securing insurance coverage for the drug (www.globenewswire.com).
Initial Launch and Uptake: VYKAT XR’s U.S. launch in 2025 saw strong early demand. In Q2 2025 (the first quarter post-approval), Soleno reported $31–$33 million in net revenue from VYKAT XR and had 646 patient start forms from ~295 prescribers by June 30 (investors.soleno.life) (investors.soleno.life). By Q3 2025, net revenue jumped to $66.0 million, and Soleno even achieved positive net income ($26 million) for the quarter (www.biospace.com). Cumulatively from approval through Q3, over 1,043 patients had enrolled (with 764 patients active on therapy as of Sept 30, 2025) and 494 unique physicians had prescribed VYKAT XR (www.biospace.com). Soleno touted the drug’s “compelling efficacy and safety profile” and broad insurance coverage (132+ million lives) as drivers of this uptake (www.biospace.com). The strong revenue ramp – rare for a first-year biotech launch – reflected pent-up demand in the PWS community.
Class Action Background: Allegations of Misleading Investors
Despite the promising launch, Soleno now faces a securities class action lawsuit that has raised serious red flags. The suit covers investors who bought SLNO stock between March 26, 2025 and November 4, 2025 – essentially from the drug’s approval through the post-launch period (www.prnewswire.com). The core allegation is that Soleno’s management misled investors about the Phase 3 trial results and DCCR’s safety profile. According to the complaint, during the class period Soleno “downplayed, misrepresented, and/or concealed” evidence of significant safety concerns in the DCCR trial – particularly issues of excess fluid retention in patients (robbinsllp.com). The complaint claims that as a result, the company understated DCCR’s risks – implying that treatment safety risks (like edema-related complications) were higher than disclosed, which could hurt patient adherence, physician willingness to prescribe, and the drug’s commercial viability (robbinsllp.com). In short, the lawsuit asserts Soleno painted an overly optimistic picture of DCCR’s safety/viability and failed to warn investors of material risks (including potential patient discontinuations, regulatory backlash, and reputational damage) (robbinsllp.com).
The “Truth” Emerges: The class action was triggered by events in late 2025 that corrected these alleged misrepresentations. On August 15, 2025, Scorpion Capital (a short-seller) published a highly critical report on Soleno, which caused SLNO shares to drop significantly (rss.globenewswire.com). According to Hagens Berman (a shareholder rights firm), the Scorpion report raised “significant issues” with Soleno’s DCCR trial program and safety data (www.prnewswire.com). In the wake of this report, Soleno’s product launch momentum faltered – fewer new patients started VYKAT XR and discontinuation rates rose, as concerns spread within the PWS patient community (www.prnewswire.com). These issues became fully apparent when Soleno reported Q3 2025 results on November 4, 2025. In that report (and the accompanying call), management acknowledged a “disruption” in the drug’s launch trajectory due to the Scorpion Capital report, citing a lower number of patient start forms and increased patient drop-offs after mid-August (www.prnewswire.com). On this news – effectively a confirmation that safety worries were impacting the launch – Soleno’s stock price plummeted over 26% in a single day (www.prnewswire.com). This sharp decline on Nov 4–5, 2025 marks the end of the class period and is the basis for shareholders’ alleged losses.
It’s important to note that Soleno’s FDA approval of DCCR indicates the FDA was aware of the drug’s side effects (including fluid retention) and deemed the benefits acceptable. However, the class action focuses on what Soleno told investors, not regulators. The suit will delve into whether Soleno’s executives knew about and insufficiently disclosed the extent of side effects or risks to DCCR’s commercial success. If internal data (or whistleblower evidence) shows they were aware of serious red flags (like high dropout rates or necessary label warnings) and failed to communicate them, there could be liability. Soleno has not yet given its legal response, but it will likely argue it complied with disclosure requirements and that any launch hiccups were due to an external short-seller campaign rather than fraud. The lead plaintiff deadline is May 5, 2026 (www.prnewswire.com), so this case is in early stages. For investors, the lawsuit underscores credibility concerns with management’s communications and puts a legal overhang on the stock.
Dividend Policy and Shareholder Returns
Dividend History: Soleno Therapeutics has never paid a dividend. This is typical for clinical-stage and early commercial biotech companies, which prioritize reinvesting in R&D and commercialization over cash distributions. Financial data sources show Soleno’s dividend yield is 0% (no dividends) (www.cnbc.com). Given Soleno only recently turned profitable and still has significant growth investments ahead (and now legal expenses), a regular dividend is unlikely in the foreseeable future.
However, Soleno did take a notable shareholder-friendly action in late 2025: a $100 million share repurchase. In November 2025, amid the post-Scorpion stock slump, the company announced an Accelerated Share Repurchase (ASR) program (www.globenewswire.com). They deployed $100M to buy back stock, and by year-end 2025 the transaction was essentially completed (www.globenewswire.com). This buyback is significant – it signals that management believed the shares were undervalued after the 26% plunge, and it returned some capital to shareholders in lieu of dividends. The repurchase reduced the outstanding share count modestly (offsetting some dilution from recent equity raises) and likely provided support to the share price. It’s unusual to see a small-cap biotech with one product initiate a large buyback, but Soleno’s cash-rich balance sheet (discussed below) made it feasible. Investors should view this as a one-off capital return move; long-term, Soleno’s ability to pay dividends will depend on sustained earnings and the outcome of its growth initiatives. For now, shareholders’ “yield” is coming via stock buybacks rather than cash dividends.
(Note: AFFO/FFO metrics are not applicable here – those are REIT cash flow measures. Soleno’s focus should be on conventional earnings and cash flow metrics now that it has product revenue.)
Financial Position: Leverage, Liquidity, and Coverage
Balance Sheet Strength: Soleno entered 2025 with a significant war chest thanks to proactive financing ahead of DCCR’s approval. In 2024, Soleno raised ~$159 million in an equity offering at $46/share (www.globenewswire.com), and in December 2024 it secured a large credit facility with Oxford Finance for up to $200 million (www.globenewswire.com). Under that loan agreement, Soleno drew an initial $50 million in late 2024, and additional tranches of $50M + $25M were structured to become available upon DCCR’s FDA approval (with another $25M tied to future sales milestones, and a final $50M at Oxford’s discretion) (www.globenewswire.com). After DCCR was approved in March 2025, Soleno had the option to tap more of this debt facility, but notably by mid-2025 it still had only $50M of debt outstanding (investors.soleno.life) – suggesting the company did not immediately draw the extra contingent debt, likely because its cash position was already robust.
By year-end 2025, Soleno’s balance sheet was extremely liquid. The company reported $506.1 million in cash, equivalents, and marketable securities as of Dec 31, 2025 (www.globenewswire.com). This includes proceeds from a $230 million equity offering completed in 2025 (timing not specified in the PR, but likely around mid-year) (www.biospace.com), plus cash generated from operations (Soleno produced positive operating cash flow in Q4). After the ~$100M share buyback, Soleno still holds over half a billion in cash. Against this, its debt remains about $50M (unless it later drew more; no indication yet of additional draws). Net cash is therefore around $456M, which gives Soleno a substantial cushion.
Leverage & Maturities: With only ~$50M in debt and over $500M in cash, Soleno’s leverage is minimal in net terms. The Oxford term loan carries typical biotech lender terms: an interest-only period for several years followed by amortization. Specifically, if DCCR hit a certain milestone by late 2025 (presumably the approval, which occurred), the loan’s principal repayments were deferred such that maturity extends to December 2030 (otherwise it would mature in 2029) (www.sec.gov). In either case, there are no near-term debt maturities – the loan won’t require principal repayment until at least 2029, giving Soleno long-term financial flexibility. Interest expense on the $50M is manageable (likely on the order of $5–6M annually, given typical mid-single-digit to low-double-digit interest rates). In fact, Soleno earned enough interest income on its large cash pile in 2025 to more than offset its interest expense (www.globenewswire.com) – effectively, the company is in a net interest income position.
Coverage: Since Soleno just turned profitable, traditional coverage ratios (EBIT/interest) are not meaningful historically. But given the Q4 2025 operating cash flow of $48.7M (www.globenewswire.com) and full-year EBITDA well above interest costs, interest coverage is strong. Even under downside scenarios, Soleno’s huge cash reserve could service debt interest many times over. There is no dividend obligation to “cover” (as noted, no dividend payouts), and the company’s only fixed financial outflows are debt interest and ongoing operating expenses. With positive cash flow from product sales and ample cash, Soleno appears capable of funding its operations, pipeline R&D, and any legal costs from the class action without liquidity strain. In short, Soleno’s financial position is solid – low leverage, long-dated debt, and abundant liquidity – which is a key comfort for investors amid the current legal uncertainties.
Operating Performance and Valuation Metrics
Recent Financial Results: Despite the controversy, Soleno’s operational performance in 2025 was impressive for a first-year launch. In Q4 2025, the company generated $91.7 million in net revenue from VYKAT XR, bringing full-year 2025 sales to $190.4 million (April–Dec post-approval) (www.globenewswire.com). For context, that revenue was achieved with 1,250 total patient start forms since launch and 859 active patients on therapy at year-end (www.globenewswire.com). Soleno actually achieved profitability in its first commercial year – posting $20.9 million in net income for full-year 2025 (www.globenewswire.com). This was aided by strong gross margins (as is typical for rare disease drugs priced at hundreds of thousands of dollars annually) and controlled expenses. By Q4, the company’s quarterly cash flow from operations was nearly $49M positive (www.globenewswire.com), indicating the product is already self-funding its commercial costs.
Growth Trajectory: The quarter-by-quarter trend shows rapid early growth but also some impact from the aforementioned launch disruption. New patient starts slowed in Q4 (207 new start forms in Q4 vs 397 in Q3) and discontinuations rose – net active patients grew to 859 from 764 in Q3 (+95 net, implying ~100+ patients stopped therapy in Q4) (www.globenewswire.com). Nonetheless, revenue in Q4 grew sequentially (up ~39% from Q3’s $66M to $92M). This suggests that despite fewer new patients, the revenue base expanded as earlier cohorts stayed on therapy for more of the quarter (and possibly due to inventory dynamics or higher pricing effective in Q4). The key question is whether growth can reaccelerate once the panic from the Scorpion report subsides, or if safety concerns will cap the adoption rate. If the dropout rate remains high and prescriber enthusiasm is dampened, future revenue might plateau below initial bullish expectations. However, if Soleno can reassure physicians and caregivers about managing side effects (e.g. with diuretics for fluid retention) and if the drug’s benefits prove compelling, the long-term patient pool could expand toward the total PWS population. (Estimates of PWS prevalence range from 7,000 to 20,000 in the U.S., so VYKAT XR still has significant runway if it can penetrate that market.)
Valuation: As of late 2025/early 2026, SLNO stock trades around the high-$40s to low-$60s per share (it closed near $49 at end of 2025, and has recently bounced around $60) (finance.yahoo.com) (www.cnbc.com). With roughly ~55 million shares outstanding, this implies a market capitalization near $2.6–3.3 billion (finance.yahoo.com). Soleno’s enterprise value (EV) is lower (~$2.1–2.8B) after netting out its $506M cash. Based on 2025 sales of $190M, the stock is trading at a EV/revenue multiple of ~11–15x. This is a rich multiple in absolute terms, reflecting the expectation of steep growth for an orphan drug with little competition. However, it’s not unusual for a biotech with a first-in-class therapy and potential global expansion – investors may be pricing in a path to peak sales in the hundreds of millions or beyond, plus pipeline optionality. In terms of earnings, the trailing P/E is not meaningful yet since 2025 included start-up costs (Yahoo Finance shows a negative trailing EPS) (finance.yahoo.com). Forward earnings will depend on how margins hold up as Soleno scales its salesforce and perhaps expands indications. For a rough gauge: if Soleno can sustain ~$20M+ annual profit at this early stage, the current market cap implies a very high earnings multiple (100+). But if profits were to grow into the ~$100M+ range over the next few years (which would require revenue climbing toward $500M and decent margins), the valuation would normalize.
Comparables: There are no direct competitors with an approved PWS hyperphagia drug yet, which gives Soleno monopoly pricing power in this niche – a factor supporting its valuation. That said, investors may benchmark SLNO against other rare-disease biotechs with a single commercial product. Many of those trade at high price-to-sales ratios initially but eventually settle in the 4–8x sales range as growth moderates. Soleno’s current ~12x EV/Sales suggests the market is still factoring in a robust growth trajectory. It’s worth noting Soleno’s cash per share is substantial (around $9–$10/share in cash), which provides downside protection and can be deployed for growth (or further buybacks). In summary, SLNO’s valuation is elevated, baking in optimism about VYKAT XR’s potential, but that optimism is tempered by the recent concerns – hence the stock’s volatility. Investors should watch upcoming earnings reports for trends in patient counts and any guidance the company gives on sales or margins, as these will drive how the multiples evolve.
Risks, Red Flags, and Open Questions
The class action and its underlying issues highlight several key risks and red flags for investors:
– Safety and Sustainability of DCCR (VYKAT XR): The biggest risk is that DCCR’s side effects – especially fluid retention/edema – could significantly limit its long-term commercial success. The class action allegations suggest Soleno knew edema was a serious issue in trials (possibly leading to higher blood pressure, heart strain, etc.) and did not fully disclose this (robbinsllp.com). Indeed, real-world use is now indicating a meaningful dropout rate (nearly one-third of patients who started have discontinued by year-end 2025). If a large percentage of patients cannot tolerate the drug or choose to stop it, the effective patient pool (and thus peak sales) will be much smaller than initial demand indicated. This could also draw regulatory scrutiny: the FDA could mandate additional warning labels or risk mitigation measures if post-market data show unforeseen safety problems. Adverse regulatory actions – while not happening yet – remain a risk if safety signals worsen (robbinsllp.com). For investors, a critical question is whether the PWS community will fully embrace VYKAT XR or view it as a last resort due to side effects. We will learn more as more patients go on drug and stay on for longer durations.
– Management Credibility and Transparency: The sequence of events (strong promotional messaging followed by a short-seller exposing issues) raises concerns about management’s transparency. The CEO’s upbeat statements in Q3 2025 about a “compelling safety profile” (www.biospace.com), contrasted with the quiet admission of launch “disruption” only after being prompted by an external report, is a red flag. Investors must assess whether this was an isolated lapse or indicative of a culture of overly rosy disclosures. The ongoing class action will keep attention on every statement the company makes. It may also distract management or lead to more conservative guidance to avoid further liability. On the positive side, Soleno’s board has taken steps like adding experienced biotech executives (e.g., a new Lead Independent Director and Audit Committee member in 2024) (www.globenewswire.com), which could improve oversight. But until the lawsuit is resolved, an overhang of distrust may persist, possibly keeping the stock’s risk premium higher.
– Concentration Risk – One Product Company: Soleno is currently a one-product company; its fortunes are entirely tied to DCCR/VYKAT XR. This amplifies the impact of any issue with that product. Competitors are also in development – for example, other biotechs have tried oxytocin analogs and other approaches for PWS in the past. While no direct rival is approved yet, it’s a space that could see new treatments in coming years. If a safer or more effective therapy emerges, Soleno could see its market evaporate. Even internally, Soleno recognizes the need to diversify: management has stated plans to pursue approval in other territories (EU next) and to evaluate DCCR in additional high-need rare diseases to expand its pipeline (www.globenewswire.com). These initiatives could unlock new growth, but come with development risk and will take time. Until then, any hiccup (regulatory, manufacturing, etc.) with VYKAT XR would have an outsized effect on Soleno’s revenues. Investors should monitor Soleno’s progress in EU regulatory filings (an EMA decision will be an important catalyst) and any pipeline announcements beyond PWS.
– Share Price Volatility and Legal Overhang: The events of 2025 showed SLNO can be extremely volatile. It ran up on FDA approval and commercial success, then plunged on a single report’s revelations. Going forward, the ongoing class action lawsuit introduces uncertainty – while the direct financial cost (settlement or damages) might be covered by insurance or be modest relative to cash, the headline risk can whipsaw the stock. For instance, as court filings emerge or if any negative emails/evidence come out, sentiment could suffer. Conversely, a quick dismissal of the case or a small settlement could remove the overhang. Investors need to be prepared for news-driven swings. The company’s move to repurchase shares in Nov 2025 suggests they may act to stabilize the stock if they feel it’s undervalued, which is a reassuring sign. Still, legal processes can drag on for years, and there is no guarantee of the outcome. This is a risk mainly to the stock’s perception – the fundamental impact of the lawsuit is likely limited to legal fees and potential settlement (perhaps in the tens of millions, which Soleno can afford). The bigger “risk” it underscores is the one above: that there may have been undisclosed negatives in the business.
– Other Risks: Standard biotech risks also apply. These include intellectual property risk (patents on DCCR – any challenges or limited term could affect the long run), manufacturing or supply issues, and pricing/reimbursement risk. The Q3 10-Q even warned that any supply disruptions or capacity constraints could hurt sales (www.sec.gov). Additionally, as a novel therapy, insurers might impose coverage restrictions over time, or payers might push back on price (especially if outcomes in the real world don’t justify cost). So far, Soleno has achieved broad coverage (185+ million insured lives by Q4 (www.globenewswire.com)), but U.S. drug pricing pressures are a background risk. Finally, execution risk in launching in Europe or other markets looms – different regulatory standards and smaller markets could make it challenging to replicate U.S. success internationally.
Conclusion: What This Means for Investors
For investors in SLNO, the class action lawsuit is both a warning flag and a catalyst to reassess the investment thesis. On one hand, Soleno Therapeutics has demonstrated that it can bring a drug to market and generate significant revenue quickly – a rarity among small biotechs. The PWS community’s initial embrace of VYKAT XR validates a real unmet need and suggests a sizable revenue opportunity if managed well. The company’s financial foundation is strong (cash-rich, now profitable), which provides resilience and flexibility to weather challenges (www.globenewswire.com). In fact, Soleno’s ability to self-fund and even return capital (via buybacks) is a green flag that sets it apart from typical cash-burning biotechs. These positives mean that if Soleno can resolve or mitigate the concerns raised, there is substantial upside in fulfilling the drug’s potential – especially with geographic expansion (EU approval efforts) and possibly new indications on the horizon (www.globenewswire.com).
On the other hand, the lawsuit spotlights the risk that Soleno’s management may have been overly optimistic or even negligent in communicating risks. Trust once broken is hard to fully regain. Investors should keep a close eye on how management addresses the safety issues going forward – are they proactively updating on adverse events? providing guidance on discontinuation rates? engaging openly with the patient community to rebuild confidence? The outcome of the class action (likely a settlement a year or two from now) will be less important than the underlying issue: can VYKAT XR deliver durable, safe benefits to patients over time? If the answer is “yes, with proper management,” then Soleno’s current challenges may prove temporary setbacks. In that scenario, today’s valuation – while not cheap – could be justified by a rare disease franchise that dominates a niche market globally and possibly extends to other disorders. If the answer is “no, the drug’s problems limit its use,” then Soleno could follow a classic boom-bust biotech pattern, with revenue peaking early and declining, and the stock retracing as growth evaporates.
Key open questions for investors include:
– Will patient uptake reaccelerate? Soleno’s Q1–Q2 2026 metrics (patient starts and actives) will reveal whether the Q4 slowdown was temporary. Any stabilization or improvement in net patient growth would indicate the worst impact of the Scorpion report might be over. Conversely, continued high discontinuation or plateauing new starts would suggest an enduring issue.
– How will Soleno leverage its huge cash pile? The company has $500M+ in cash – almost 25% of its market cap – and no urgent need for it to support current operations. Management could consider additional share repurchases (beyond the $100M done) if they believe in the stock, or they might invest in pipeline development or acquisitions to diversify away from a single product. Investors will watch for strategic uses of this capital. A risk is that they squander it on an ill-advised acquisition; a positive would be if they license or develop a synergistic rare disease therapy that adds value.
– Can Soleno rebuild confidence with stakeholders? This includes not just investors (addressing the lawsuit) but also doctors and patients. If the PWS community remains hesitant because of safety fears, Soleno might need to initiate educational or support programs (perhaps study the use of adjunct therapies to manage side effects). Prescriber reluctance was cited as a risk from the alleged lack of transparency (robbinsllp.com). Overcoming that is crucial for long-term adoption. Any signals such as specialist endorsements, improved patient retention rates, or real-world studies demonstrating manageable safety could be catalysts that restore faith.
– What is the long-term earnings power? Now that Soleno has broken even, how profitable can this business become? Rare disease drugs often have 80%+ gross margins. Soleno’s Q3 profit gives a glimpse of high operating leverage. If the company can continue to grow sales without proportional expense growth (especially post-launch marketing), margins could expand. This could eventually support the initiation of dividends or larger buybacks, truly rewarding shareholders – but it all hinges on the top-line trajectory holding up.
In summary, SLNO presents a high-risk, high-reward profile at this juncture. The class action is a symptom of the underlying tension between tremendous promise and significant peril. Investors should be prepared for volatility as the legal process and commercial progress unfold. Those who are bullish might argue that the selloff and headline risk have created an opportunity to invest in a unique orphan drug story with strong finances. Bears will argue that where there’s smoke (lawsuit) there’s fire, and that the drug’s issues could stunt its growth. Prudent investors will likely take a wait-and-see approach – monitoring upcoming earnings, legal filings, and clinical updates for clarity. Until more is known, position sizing and risk management are key; it may be wise to treat SLNO as a speculative position rather than a core holding.
Ultimately, what this means for investors is that due diligence is more important than ever. It’s crucial to separate the legal drama from the business fundamentals. The class action alone may not derail Soleno, but the factors behind it (drug safety and management honesty) absolutely could. Investors should keep an eye on FDA signals, such as any post-marketing safety communications, and on Soleno’s own transparency in disclosures going forward. If Soleno navigates this minefield successfully – addressing concerns and delivering on growth – it could emerge stronger, with a de-risked profile and robust cash flows. If not, the stock’s earlier gains could prove fleeting. In the meantime, expect the cloud of litigation and trust deficit to hang over SLNO, meaning the stock may trade as much on news and sentiment as on standard fundamentals in the near term. Caution and careful observation are warranted as this story continues to unfold.
Sources:
– Soleno Therapeutics, Inc. press release, Q3 2025 Financial Results & VYKAT XR Launch Update, Nov. 4, 2025 – financial and operational metrics (www.biospace.com) (www.biospace.com). – Soleno Therapeutics, Inc. press release, Q4 and Full-Year 2025 Results & Launch Update, Feb. 25, 2026 – revenue, patient counts, profit, and share buyback details (www.globenewswire.com) (www.globenewswire.com). – Robbins LLP Class Action Notice, Mar. 11, 2026 – summary of lawsuit allegations that Soleno “misled investors regarding the viability and efficacy” of Phase 3 DCCR (safety issues: fluid retention) (robbinsllp.com). – Kessler Topaz class action announcement, Mar. 14, 2026 – notes that on Nov 4, 2025, Soleno revealed the Scorpion Capital report’s impact (higher discontinuations, slowed starts) which led to a 26% stock drop (www.prnewswire.com). – Hagens Berman alert, Aug. 19, 2025 – confirms “On August 15, 2025, shares in Soleno dropped following a highly critical report by Scorpion Capital” (investigation into whether Soleno misled investors) (rss.globenewswire.com). – Soleno Therapeutics, Inc. press release, Q4 2024 Results & Corporate Update, Feb. 27, 2025 – details of the $200M Oxford Finance loan facility and 2024 equity offering (www.globenewswire.com) (www.globenewswire.com). – Yahoo Finance and CNBC data for SLNO – market cap ~$2.6B, no dividend, stock volatility (finance.yahoo.com) (www.cnbc.com). – Soleno Therapeutics, Inc. press release, Preliminary Q2 2025 Results, July 10, 2025 – first sales of VYKAT XR and June 30 cash/debt figures (investors.soleno.life) (investors.soleno.life). – Soleno Therapeutics, Inc. 10-Q for Q3 2025 (filed Nov 2025) – indicates term loan repayment timeline (interest-only through 2029/2030) (www.sec.gov) and interest income/expense; risk factor excerpts on supply disruptions (www.sec.gov). – Company statements on strategy: pursuing EU approval and exploring DCCR in other rare diseases (expanding pipeline) (www.globenewswire.com).
For informational purposes only; not investment advice.